Technology evaluation: mapatumumab, Human Genome Sciences/GlaxoSmithKline/Takeda

Curr Opin Mol Ther. 2005 Oct;7(5):502-10.

Abstract

Human Genome Sciences and GlaxoSmithKline, under license from Cambridge Antibody Technology, are developing mapatumumab, the intravenously administered lead from a series of human monoclonal antibody tumor necrosis factor-related apoptosis-inducing ligand receptor 1 agonists, for the potential treatment of cancer. The therapy is currently undergoing phase II clinical trials. Takeda is developing mapatumumab in Japan.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / pharmacokinetics
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use*
  • Apoptosis / drug effects
  • Apoptosis Regulatory Proteins / agonists
  • Apoptosis Regulatory Proteins / immunology*
  • Apoptosis Regulatory Proteins / pharmacology
  • Cell Line, Tumor
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Contraindications
  • Dose-Response Relationship, Drug
  • Humans
  • Membrane Glycoproteins / agonists
  • Membrane Glycoproteins / immunology*
  • Membrane Glycoproteins / pharmacology
  • Neoplasms / drug therapy*
  • TNF-Related Apoptosis-Inducing Ligand
  • Tumor Necrosis Factor-alpha / agonists
  • Tumor Necrosis Factor-alpha / immunology*
  • Tumor Necrosis Factor-alpha / pharmacology
  • Xenograft Model Antitumor Assays

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Apoptosis Regulatory Proteins
  • Membrane Glycoproteins
  • TNF-Related Apoptosis-Inducing Ligand
  • TNFSF10 protein, human
  • Tumor Necrosis Factor-alpha
  • mapatumumab